Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255624898> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4255624898 endingPage "35" @default.
- W4255624898 startingPage "29" @default.
- W4255624898 abstract "After completing this course, the reader will be able to: Identify the rationale for exploring alternative dosing schedules for topotecan. Identify which alternative schedules are being explored and have the most promise. Identify the tolerance and antitumor activity of alternative dosing regimens for topotecan. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Topotecan has demonstrated efficacy in the treatment of both platinum-sensitive and platinum-resistant recurrent ovarian cancer. However, the optimal dosing for topotecan has not been established. The standard dosing regimen is 1.5 mg/m2/day on days 1-5 of a 21-day cycle, with response rates ranging from 13%-33%. Although the resulting hematologic toxicities are reversible and noncumulative, this schedule is associated with significant myelosuppression. Ongoing clinical phase I and II trials have evaluated alternative dosing schedules such as the 21-day 24-hour continuous intravenous (c.i.v.), the 3-day i.v. bolus, the weekly 72-hour c.i.v., the weekly 24-hour c.i.v., and the weekly bolus i.v. regimens. Prolonged exposure to topotecan has been shown to increase the efficacy of topotecan, whereas shorter regimens decrease exposure to the drug and therefore decrease toxicity. Preliminary studies investigating the weekly bolus i.v. regimen have demonstrated response rates comparable with those achieved with the standard dosing regimen, with a lower frequency of severe toxicity. Although randomized, controlled comparative trials are necessary to determine relative efficacy, results from studies utilizing other alternative regimens are less encouraging, especially for lower-risk patients with platinum-sensitive ovarian cancer who are likely to tolerate higher doses of topotecan. Optimizing the dosing regimen will also increase the quality of life for the patient through increased efficacy, decreased toxicity, and increased convenience of administration. Continued investigation of the weekly i.v. bolus is needed to fully elucidate the contribution of this regimen to the current armamentarium used in the treatment of patients with relapsed ovarian cancer." @default.
- W4255624898 created "2022-05-12" @default.
- W4255624898 creator A5052303363 @default.
- W4255624898 date "2002-10-01" @default.
- W4255624898 modified "2023-09-25" @default.
- W4255624898 title "Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer" @default.
- W4255624898 doi "https://doi.org/10.1634/theoncologist.7-2004-29" @default.
- W4255624898 hasPublicationYear "2002" @default.
- W4255624898 type Work @default.
- W4255624898 citedByCount "0" @default.
- W4255624898 crossrefType "journal-article" @default.
- W4255624898 hasAuthorship W4255624898A5052303363 @default.
- W4255624898 hasBestOaLocation W42556248981 @default.
- W4255624898 hasConcept C121608353 @default.
- W4255624898 hasConcept C126322002 @default.
- W4255624898 hasConcept C143998085 @default.
- W4255624898 hasConcept C2776694085 @default.
- W4255624898 hasConcept C2777288759 @default.
- W4255624898 hasConcept C2780427987 @default.
- W4255624898 hasConcept C2781209748 @default.
- W4255624898 hasConcept C2781413609 @default.
- W4255624898 hasConcept C29730261 @default.
- W4255624898 hasConcept C43376680 @default.
- W4255624898 hasConcept C535046627 @default.
- W4255624898 hasConcept C71924100 @default.
- W4255624898 hasConcept C98274493 @default.
- W4255624898 hasConceptScore W4255624898C121608353 @default.
- W4255624898 hasConceptScore W4255624898C126322002 @default.
- W4255624898 hasConceptScore W4255624898C143998085 @default.
- W4255624898 hasConceptScore W4255624898C2776694085 @default.
- W4255624898 hasConceptScore W4255624898C2777288759 @default.
- W4255624898 hasConceptScore W4255624898C2780427987 @default.
- W4255624898 hasConceptScore W4255624898C2781209748 @default.
- W4255624898 hasConceptScore W4255624898C2781413609 @default.
- W4255624898 hasConceptScore W4255624898C29730261 @default.
- W4255624898 hasConceptScore W4255624898C43376680 @default.
- W4255624898 hasConceptScore W4255624898C535046627 @default.
- W4255624898 hasConceptScore W4255624898C71924100 @default.
- W4255624898 hasConceptScore W4255624898C98274493 @default.
- W4255624898 hasIssue "90005" @default.
- W4255624898 hasLocation W42556248981 @default.
- W4255624898 hasOpenAccess W4255624898 @default.
- W4255624898 hasPrimaryLocation W42556248981 @default.
- W4255624898 hasRelatedWork W182989684 @default.
- W4255624898 hasRelatedWork W1998409936 @default.
- W4255624898 hasRelatedWork W2073197076 @default.
- W4255624898 hasRelatedWork W2141722396 @default.
- W4255624898 hasRelatedWork W2155041167 @default.
- W4255624898 hasRelatedWork W2466209479 @default.
- W4255624898 hasRelatedWork W2902585176 @default.
- W4255624898 hasRelatedWork W4246529798 @default.
- W4255624898 hasRelatedWork W4255624898 @default.
- W4255624898 hasRelatedWork W4313564772 @default.
- W4255624898 hasVolume "7" @default.
- W4255624898 isParatext "false" @default.
- W4255624898 isRetracted "false" @default.
- W4255624898 workType "article" @default.